Restless Leg Syndrome | Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome
Restless Leg Syndrome research study
What is the primary objective of this study?
The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.
Who is eligible to participate?
Inclusion Criteria: 1. Outpatients with a diagnosis of primary restless leg syndrome using the International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria8. 2. RLS symptoms ≥ 15 nights of the month prior to study enrollment and for ≥ 4 of 7 consecutive nights in the week prior to study enrollment (if untreated). 3. Age 18 years to 80 years. 4. International Restless Legs Scale (IRLS) Total severity score of ≥ 15 (moderate to severe severity). 8 5. Had significant sleep disturbance on item 4 of IRLS.8 6. Women of child-bearing potential must use a reliable method of contraception. 7. Informed consent. Subject must be willing and able to complete all study procedures. Exclusion Criteria: 1. Any illness that in the investigator's opinion preclude participation in this study. 2. Subjects with non-RLS-related sleep disorders (e.g., sleep apnea) 3. Subjects with neurological diseases or movement disorders other than RLS (e.g., diabetic neuropathy, Parkinson's disease, multiple sclerosis, dyskinesias, and dystonias) 4. Pregnancy or lactation. 5. Concurrent participation in another clinical study. 6. Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini-Mental State Examination scores less than 27). 7. Legal incapacity or limited legal capacity. 8. History of RLS symptom augmentation or early-morning rebound with previous dopamine-agonist treatment. 9. Clinically significant abnormalities in renal function. 3,8,10 10. Presence of severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease. 11. Concomitant treatment with drugs known to affect sleep/wake, RLS or periodic limb movements, including antidepressants. Subjects receiving treatment for RLS at screening will be required to discontinue and wash out for a minimum of 5 half-lives. 12. Body mass index greater than 34 kg/m2.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Restless Leg Syndrome
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Gabapentin immediate releaseup to 1200 mg per day
Drug:Gabapentin enacarbil extended releaseup to 1200 mg per day
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
gabapentin immediate releaseGabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
gabapentin enacarbil extended releaseHorizant is the extended release form of gabapentin enacarbil. Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
Start Date: April 2014
Phase: Phase 4
Primary Outcome: International Restless Leg Syndrome Rating Scale (IRLS)
Secondary Outcome: Restless Leg Syndrome Quality of Life Scale (RLSQoL)
Study sponsors, principal investigator, and references
Principal Investigator: Theresa Zesiewicz, MD, FAAN
Lead Sponsor: Theresa Zesiewicz